… DAPA-HF were similar to those in other contemporary HF with reduced ejection fraction (HFrEF)
registries and trials. … Consequently, DAPA-HF will test the incremental efficacy and safety …

… Using study-level published data from DAPA-HF and patient-… on fatal and non-fatal heart
failure events and renal outcomes in … subgroups from DAPA-HF and EMPEROR-Reduced trials. …

… of Adverse-outcomes in Heart Failure), the SGLT2 inhibitor … cardiovascular death or worsening
heart failure (HF) in patients who had HFrEF with and without type 2 diabetes. In this study…

… benefits of dapagliflozin in DAPA-HF were obtained regardless of … DAPA-HF was in keeping
with other reports in large cohorts of patients with HFrEF, predominantly in New York Heart …

… DAPA-HF, we could not directly assess the potential incremental value of treatment with both
dapagliflozin and sacubitril/valsartan in this trial… PARADIGM-HF and DAPA-HF trials was on …

… study, which evaluated prespecified assessments of health status using KCCQ in the DAPA-HF
trial… composite end point of cardiovascular death or worsening HF, and its components, to …

… exploratory endpoint in both DAPA-CKD and DAPA-HF trials and is the focus of this
analysis. New-onset type 2 diabetes was identified by serial trial measurements of HbA 1c (two …

… failure (HF) in patients with heart failure and reduced ejection fraction (HFrEF). In this analysis
of DAPA-HF, … secondary end point of total failure hospitalizations (first and recurrent) and …

… the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart
failure (HF) and death in patients with HF … was consistent in relation to background HF therapy. …

… Study outcomes … of an episode of worsening heart failure (HF hospitalization or an urgent
visit because of worsening HF requiring intravenous therapy) or cardiovascular (CV) death, …